Author:
Maruyama Dai,Yamauchi Nobuhiko
Reference8 articles.
1. Multiple myeloma;van de Donk;Lancet,2021
2. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial;Moreau;Lancet,2021
3. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study;Martin;Blood Cancer J,2023
4. Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3 randomised controlled trial;Yong;Lancet Haematol,2024
5. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study;Usmani;Lancet Oncol,2022